Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,829.70 -47.35 (-0.60%) Bitcoin USD
64,845.32 +3,229.16 (+5.24%) CMC Crypto 200
1,336.03 +23.41 (+1.82%)
Clover Biopharmaceuticals, Ltd. (2197.HK)
| Previous close | 0.315 |
| Open | 0.320 |
| Bid | 0.315 x N/A |
| Ask | 0.325 x N/A |
| Day's range | 0.300 - 0.340 |
| 52-week range | 0.300 - 2.040 |
| Volume | |
| Avg. volume | 1,283,506 |
| Market cap | 420.573M |
| Beta (5Y monthly) | 3.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.120 |
| Earnings date | 26 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.91 |
PR NewswireClover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary immunogenicity and safety data in the initial young adult cohort from its Phase I trial evaluating SCB-1019 – the company's bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate – which is based on Clover's Trimer-Tag vaccine tech
PR NewswireClover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company, today announced positive preliminary safety, efficacy and pharmacokinetics data in a Phase Ⅰ clinical trial evaluating SCB-219M, an innovative thrombopoietin receptor agonist (TPO-RA) mimetic bispecific Fc-fusion protein produced from CHO cells, for the treatment of cancer patients with chemotherapy-induced thrombocytopenia (CIT).
- PR Newswire
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase Ⅰ first-in-human study evaluating the company's RSV PreF-Trimer subunit vaccine candidate (SCB-1019), which is based on Clover's Trimer-Tag vaccine technology platform.
